December 12, 2018

WATCH: The Heart of PPMD’s Research – Webinar Recording

ICYMI: Yesterday, I had the privilege of hosting an in depth look at PPMD’s cardiac research priorities in Duchenne for 2019. If you were unable to join us live, I hope you will take a…

Learn More

December 10, 2018

Your gift to critical cardiac research will be matched!

When PPMD started in 1994, research to treat Duchenne muscular dystrophy was virtually nonexistent. Nearly 25 years later, we have a clinical trial pipeline full of possibility with over 25 active trials, 30+ companies, and…

Learn More

December 6, 2018

Why the Heart Matters

Disclaimer: I am a selfish person. My sons Chris and Patrick died of heart failure. I agree the primary insult was pneumonia, but their hearts were broken in so many ways that they could not…

Learn More

December 6, 2018

Wave Life Sciences Announces Positive Phase 1 Results for WVE-210201 in Duchenne Muscular Dystrophy

  Wave Life Sciences announced positive safety and tolerability results from the WVE-210201 Phase 1 clinical trial today. PPMD continues to be optimistic about the progress the team at Wave Life Sciences is making with…

Learn More

November 30, 2018

Support heart health–all gifts matched!

For the last two years, you have helped support PPMD’s Gene Therapy Initiative and because of your support, we are seeing real results, real potential, real hope. But with all the progress we have made…

Learn More

November 29, 2018

End Duchenne Tour Recap: Palo Alto, CA

PPMD headed to Palo Alto, CA for our End Duchenne Tour stop on November 3, 2018. Many families and members of the Duchenne community came together to learn about the latest information and resources for Duchenne families….

Learn More

November 29, 2018

An Update on Clinical Trial Innovation for Duchenne – a Master Protocol

PPMD is committed to making research and development of new medicines for families living with Duchenne as fast and efficient as possible.  Over the years, by listening to you, we have developed a clinical trials…

Learn More

November 28, 2018

PPMD Designates University of Virginia Children’s Hospital a Certified Duchenne Care Center

Today Parent Project Muscular Dystrophy (PPMD) named University of Virginia Children’s Hospital to be the 22nd clinic to be named a Certified Duchenne Care Center PPMD’s Certified Duchenne Care Center Program, which supports standardized, comprehensive care and services…

Learn More

November 21, 2018

Giving Thanks…for YOU!

As I write this, something is inevitably overcooking in my oven, the turkey may not be defrosted, and we are running low on Diet Coke. But amidst the craziness and chaos of the holiday, I…

Learn More

November 20, 2018

Santhera Enters into Agreement to Acquire Option for Exclusive Sub-License of Vamorolone

PPMD has learned that Santhera Pharmaceuticals and Idorsia Ltd have entered into an agreement under which Santhera will acquire the option to exclusively in-license vamorolone, currently being developed by Reveragen. Idorsia currently holds the license…

Learn More